期刊
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
卷 18, 期 4, 页码 593-599出版社
MARY ANN LIEBERT INC PUBL
DOI: 10.1089/108497803322287682
关键词
Lu-177-DOTA-Tyr(3)-octreotate; biodistribution; small cell lung cancer; animal model; radionuclide therapy
In this study the biodistribution of a somatostatin analogue, Lu-177-[DOTA(0),Tyr(3)]octreotate,was investigated in an animal model, as a possible therapeutic radiopharmaceutical. Methods: Lu-177-[DOTA(0),Tyr(3)]octreotate was injected i.v. into nude mice bearing somatostatin receptor-positive tumors of the human small cell lung cancer (SCLC) cell line NCI-H69. In addition, nontumor bearing mice were injected i.v. with (LuCl3)-Lu-177. The activity concentration in tumor and normal tissues was measured and dosimetric estimations for tumor tissue were made. Results: The tumor had higher activity concentration of Lu-177-[DOTA(0),Tyr(3)]octreotate compared to all measured normal tissues at all time points. The activity concentration in the tumor tissue was 3.7 %IA/g, 2.1 %IA/g, and 1.2 %IA/g after 24 h, 3 days and 7 days, respectively. The mean absorbed dose to a 1 g tumor was 0.3 Gy/MBq. The highest activity concentration of (LuCl3)-Lu-177 was observed in the bone marrow and increased with time. Conclusion: This study shows that Lu-177-labeled [DOTA(0),Tyr(3)]octreotate has therapeutic potential for SCLC. The study also points out the importance of optimal labeling efficiency since the high bone marrow uptake of free lutetium ions can be controlled by a high peptide-bound fraction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据